sulpiride has been researched along with Alzheimer Disease in 11 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Model predictions were used to simulate dose-response and dose-EPS." | 1.46 | A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Dunn, JT; Greaves, S; Howard, R; Kessler, R; Marsden, P; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D; Uchida, H, 2017) |
| "Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events." | 1.43 | A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Greaves, S; Howard, R; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kucwaj-Brysz, K | 1 |
| Baltrukevich, H | 1 |
| Czarnota, K | 1 |
| Handzlik, J | 1 |
| Reeves, S | 4 |
| McLachlan, E | 3 |
| Bertrand, J | 3 |
| D'Antonio, F | 3 |
| Brownings, S | 4 |
| Nair, A | 3 |
| Greaves, S | 4 |
| Smith, A | 3 |
| Taylor, D | 3 |
| Dunn, J | 1 |
| Marsden, P | 3 |
| Kessler, R | 3 |
| Howard, R | 4 |
| Dunn, JT | 2 |
| Uchida, H | 1 |
| Clark-Papasavas, C | 1 |
| Mogg, A | 1 |
| Gomes, R | 1 |
| Liu, K | 1 |
| Nwosu, B | 1 |
| Joemon, J | 1 |
| Cleij, M | 1 |
| Seeman, P | 1 |
| Monji, A | 1 |
| Takita, M | 1 |
| Samejima, T | 1 |
| Takaishi, T | 1 |
| Hashimoto, K | 1 |
| Matsunaga, H | 1 |
| Oda, M | 1 |
| Sumida, Y | 1 |
| Mizoguchi, Y | 1 |
| Kato, T | 1 |
| Horikawa, H | 1 |
| Kanba, S | 1 |
| Mauri, M | 1 |
| Mancioli, A | 1 |
| Rebecchi, V | 1 |
| Corbetta, S | 1 |
| Colombo, C | 1 |
| Bono, G | 1 |
| Lim, HK | 1 |
| Pae, CU | 1 |
| Lee, C | 1 |
| Lee, CU | 1 |
| Fujita, M | 2 |
| Shimizu, T | 2 |
| Toyoda, K | 1 |
| Motomura, N | 1 |
| Kuroda, K | 1 |
1 review available for sulpiride and Alzheimer Disease
| Article | Year |
|---|---|
Chemical update on the potential for serotonin 5-HT
Topics: Alzheimer Disease; Animals; Humans; Nootropic Agents; Receptors, Serotonin; Serotonin Antagonists; S | 2021 |
3 trials available for sulpiride and Alzheimer Disease
| Article | Year |
|---|---|
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Dopamine | 2017 |
Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Anxiety D | 2006 |
Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; | 2006 |
7 other studies available for sulpiride and Alzheimer Disease
| Article | Year |
|---|---|
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Basal Ganglia Diseases; Brain; Delusions; D | 2017 |
Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Map | 2014 |
Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease.
Topics: Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Mapping; Female; Humans; Mal | 2014 |
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Female; Healthy Volun | 2016 |
Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior; Drug Therapy, Combinatio | 2009 |
A neuroendocrinological investigation of patients with senile demantia of Alzheimer type. Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.
Topics: Aged; Alzheimer Disease; Bromocriptine; Dopamine; Female; Growth Hormone; Humans; Hypothalamus; Kine | 1986 |
[Plasma prolactin and GH response after thyrotropin-releasing hormone (TRH), L-DOPA and sulpiride in patients with senile dementia of Alzheimer type].
Topics: Aged; Alzheimer Disease; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Prolactin; Sulpiride; | 1985 |